GLSHQ — Gelesis Holdings Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $65.64m
- $25.77m
Annual income statement for Gelesis Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 21.4 | 11.2 | 25.8 |
| Cost of Revenue | |||
| Gross Profit | 19 | 1.2 | -1.79 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Total Operating Expenses | 49.7 | 96.2 | 148 |
| Operating Profit | -28.2 | -85 | -122 |
| Total Net Non Operating Interest Income / Expense | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -23.9 | -93.3 | -55.3 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -25.9 | -93.3 | -55.8 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -26.5 | -93.7 | -57.1 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -37.8 | -188 | -95.1 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.522 | -2.59 | -1.35 |
| Dividends per Share |